Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cat Allergen Exposure: EEC vs NAC
NCT02163122Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fel d 1 in allergic rhinitis (AR) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Nasal Allergen Challenge Total Nasal Symptom Score Area under the Curve and Environmental Exposure Chamber Total Nasal Symptom Score Area under the Curve. Started Jan 2015; status: completed.
02
Drugs
Fel d 1
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02163122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163122.